-
Je něco špatně v tomto záznamu ?
Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration
J. Radej, A. Krouzecky, P. Stehlik, R. Sykora, J. Chvojka, T. Karvunidis, I. Novak, M. Matejovic,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem
- MeSH
- antiinfekční látky aplikace a dávkování krev farmakokinetika MeSH
- hemofiltrace MeSH
- kritický stav MeSH
- lidé MeSH
- monitorování léčiv metody MeSH
- mykózy krev farmakoterapie metabolismus MeSH
- plocha pod křivkou MeSH
- poločas MeSH
- pyrimidiny aplikace a dávkování krev farmakokinetika MeSH
- triazoly aplikace a dávkování krev farmakokinetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
INTRODUCTION: Voriconazole represents an essential part of antimicrobial therapy in critically ill patients. The aim of this study was to exclude a significant alteration in voriconazole pharmacokinetics in critically ill patients undergoing continuous venovenous hemofiltration (CVVH). METHODS: Six patients dependent on CVVH with evidence of an invasive mycotic infection treated with intravenous voriconazole at the standard dosing regimen were investigated. The total serum concentration of voriconazole in arterial blood and the concentration in ultrafiltrate were measured by reverse-phase high-performance liquid chromatography with ultraviolet detection. The authors profiled a 5-point pharmacokinetic concentration-time curve during the 12-hour standard maintenance dosing interval and derived the basic pharmacokinetic parameters. RESULTS: The serum voriconazole concentration did not decrease <1.0 mg/L at any time point, and the mean was 4.3 ± 2.6 mg/L and the median (range) 3.6 (9.0) mg/L. The sieving coefficient of the drug did not exceed 0.30 in any patient (0.22 ± 0.08). The mean serum AUC0-12, the mean total clearance, and the mean clearance via CVVH were 53.52 ± 29.97 mg·h/L [the median (range) of 57.74 (62.34) mg·h/L], 0.11 ± 0.07 L·h-1·kg-1, and 0.007 ± 0.003 L·h-1·kg-1, respectively. The clearance by the CVVH method ranged from 4% to 20% of the total drug clearance. The disposition of voriconazole was not compromised. The mean elimination half-life was 27.58 ± 35.82 hours [the median of 13.10 (92.21) hours], and the mean distribution volume value was 3.28 ± 3.10 L/kg [the median of 2.01 (8.10) L/kg]. Marked variability in serum concentrations, elimination half-life, distribution volume, and total clearance was seen. Half of the patients showed some drug accumulation. CONCLUSIONS: The clearance of voriconazole by CVVH is not clinically significant. In view of this finding, voriconazole dose adjustment in patients undergoing the standard method of CVVH is not required. However, the observed potential for an unpredictable voriconazole accumulation suggests the usefulness for monitoring its levels in critically ill patients.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12022588
- 003
- CZ-PrNML
- 005
- 20121025092318.0
- 007
- ta
- 008
- 120806s2011 xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1097/ftd.0b013e3182205d93 $2 doi
- 035 __
- $a (PubMed)21654349
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Radej, Jaroslav $u 1st Medical Department, ICU, Charles University Medical School and Teaching Hospital, Plzen, Czech Republic. radejj@fnplzen.cz
- 245 10
- $a Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration / $c J. Radej, A. Krouzecky, P. Stehlik, R. Sykora, J. Chvojka, T. Karvunidis, I. Novak, M. Matejovic,
- 520 9_
- $a INTRODUCTION: Voriconazole represents an essential part of antimicrobial therapy in critically ill patients. The aim of this study was to exclude a significant alteration in voriconazole pharmacokinetics in critically ill patients undergoing continuous venovenous hemofiltration (CVVH). METHODS: Six patients dependent on CVVH with evidence of an invasive mycotic infection treated with intravenous voriconazole at the standard dosing regimen were investigated. The total serum concentration of voriconazole in arterial blood and the concentration in ultrafiltrate were measured by reverse-phase high-performance liquid chromatography with ultraviolet detection. The authors profiled a 5-point pharmacokinetic concentration-time curve during the 12-hour standard maintenance dosing interval and derived the basic pharmacokinetic parameters. RESULTS: The serum voriconazole concentration did not decrease <1.0 mg/L at any time point, and the mean was 4.3 ± 2.6 mg/L and the median (range) 3.6 (9.0) mg/L. The sieving coefficient of the drug did not exceed 0.30 in any patient (0.22 ± 0.08). The mean serum AUC0-12, the mean total clearance, and the mean clearance via CVVH were 53.52 ± 29.97 mg·h/L [the median (range) of 57.74 (62.34) mg·h/L], 0.11 ± 0.07 L·h-1·kg-1, and 0.007 ± 0.003 L·h-1·kg-1, respectively. The clearance by the CVVH method ranged from 4% to 20% of the total drug clearance. The disposition of voriconazole was not compromised. The mean elimination half-life was 27.58 ± 35.82 hours [the median of 13.10 (92.21) hours], and the mean distribution volume value was 3.28 ± 3.10 L/kg [the median of 2.01 (8.10) L/kg]. Marked variability in serum concentrations, elimination half-life, distribution volume, and total clearance was seen. Half of the patients showed some drug accumulation. CONCLUSIONS: The clearance of voriconazole by CVVH is not clinically significant. In view of this finding, voriconazole dose adjustment in patients undergoing the standard method of CVVH is not required. However, the observed potential for an unpredictable voriconazole accumulation suggests the usefulness for monitoring its levels in critically ill patients.
- 650 _2
- $a antiinfekční látky $x aplikace a dávkování $x krev $x farmakokinetika $7 D000890
- 650 _2
- $a plocha pod křivkou $7 D019540
- 650 _2
- $a kritický stav $7 D016638
- 650 _2
- $a monitorování léčiv $x metody $7 D016903
- 650 _2
- $a poločas $7 D006207
- 650 _2
- $a hemofiltrace $7 D006440
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mykózy $x krev $x farmakoterapie $x metabolismus $7 D009181
- 650 _2
- $a pyrimidiny $x aplikace a dávkování $x krev $x farmakokinetika $7 D011743
- 650 _2
- $a triazoly $x aplikace a dávkování $x krev $x farmakokinetika $7 D014230
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Krouzecky, Ales
- 700 1_
- $a Stehlik, Pavel
- 700 1_
- $a Sykora, Roman
- 700 1_
- $a Chvojka, Jiri
- 700 1_
- $a Karvunidis, Thomas
- 700 1_
- $a Novak, Ivan
- 700 1_
- $a Matejovic, Martin
- 773 0_
- $w MED00004503 $t Therapeutic drug monitoring $x 1536-3694 $g Roč. 33, č. 4 (2011), s. 393-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21654349 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120806 $b ABA008
- 991 __
- $a 20121025092523 $b ABA008
- 999 __
- $a ok $b bmc $g 944501 $s 779885
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 33 $c 4 $d 393-7 $i 1536-3694 $m Therapeutic drug monitoring $n Ther Drug Monit $x MED00004503
- LZP __
- $a Pubmed-20120806/12/01